Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2-Positive Breast Cancer

A prophylactic treatment of loperamide plus budesonide reduced the rate of grade-3 diarrhea associated with neratinib, according to the results of the phase II CONTROL trial, which were presented at the 2016 San Antonio Breast Cancer Symposium. The combination regimen reduced the rate of grade ≥3 diarrhea associated with neratinib to 15% compared with 39.9% observed in the ExteNET trial.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.